
Opinion|Videos|February 7, 2025
GOLD 2025 Report: Dupilumab, a New Treatment in COPD
Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The 2025 GOLD recommendations include the addition of dupilumab as the first biologic treatment to reduce the frequency of COPD exacerbations in stable COPD.
- Discuss clinical outcomes with dupilumab in the BOREAS and NOTUS phase 3 trials.
Advertisement
Related to this article

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

